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Abstract
Background: Equine Multiple Congenital Ocular Anomalies (MCOA) syndrome consists of a diverse set
of abnormalities predominantly localized to the frontal part of the eye. The disease is in agreement with a
codominant mode of inheritance in our horse material. Animals presumed to be heterozygous for the
mutant allele have cysts originating from the temporal ciliary body, peripheral retina and/or iris. In
contrast, animals predicted to be homozygous for the disease-causing allele possess a wide range of
multiple abnormalities, including iridociliary and/or peripheral retinal cysts, iridocorneal angle
abnormalities, cornea globosa, iris hypoplasia and congenital cataracts. MCOA is most common in the
Rocky Mountain horse breed where it occurs at a high frequency among Silver colored horses. The Silver
coat color is associated with mutations in PMEL17 that resides on ECA6q23. To map the MCOA locus we
analyzed 11 genetic markers on ECA6q and herein describe a chromosome interval for the MCOA locus.
Results: We performed linkage analysis within 17 paternal half-sib families of the Rocky Mountain horse
breed. More than half of the 131 offspring had the Cyst phenotype and about one third had MCOA.
Segregation data were obtained by genotyping 10 microsatellite markers most of which are positioned on
ECA6q22-23, as well as the missense mutation for the Silver phenotype in PMEL17. Significant linkage was
found between the MCOA locus and eight of the genetic markers, where marker UPP5 (Theta = 0, z = 12.3),
PMEL17ex11 (Theta = 0, z = 19.0) and UPP6 (Theta = 0, z = 17.5) showed complete linkage with the MCOA
locus. DNA sequencing of PMEL17 in affected and healthy control individuals did not reveal any additional
mutations than the two mutations associated with the Silver coat color.
Conclusion: The MCOA locus can with high confidence be positioned within a 4.9 megabase (Mb) interval
on ECA6q. The genotype data on UPP5, PMEL17ex11 and UPP6 strongly support the hypothesis that
horses with the Cyst phenotype are heterozygous for the mutant allele and that horses with the MCOA
phenotype are homozygous for the mutant allele.
Published: 19 December 2008
BMC Genetics 2008, 9:88 doi:10.1186/1471-2156-9-88
Received: 1 July 2008
Accepted: 19 December 2008
This article is available from: http://www.biomedcentral.com/1471-2156/9/88
© 2008 Andersson et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genetics 2008, 9:88 http://www.biomedcentral.com/1471-2156/9/88
Page 2 of 10
(page number not for citation purposes)
Background
In 1999, Ramsey et al. [1] described a wide range of con-
genital ocular defects in the Rocky Mountain horse origi-
nally referred to as Anterior Segment Dysgenesis
syndrome. More recently, the syndrome has been referred
to as Multiple Congenital Ocular Anomalies (MCOA), as
described by Grahn et al. [2]. Ocular abnormalities are in
general quite rare in horses, accounting for less than five
percent of the congenital disorders reported in horses
[3,4]. Conversely, eye abnormalities were encountered in
approximately half of the 514 horses examined in Ram-
sey's study. The high incidence of ocular abnormalities in
this breed is most likely due to a founder effect. Pedigree
examination has revealed that a large proportion of the
affected horses have a common ancestor, a stallion that is
one of the few founders of the Rocky Mountain horse
breed. The fact that five out of seven of the ancestral stal-
lion's first-generation offspring had ocular abnormalities
suggests that this individual did indeed carry the mutant
allele. Extensive breeding from this foundation sire's off-
spring has propagated the causative mutation(s), leading
to a high frequency of MCOA syndrome in the Rocky
Mountain horse population. There are numerous exam-
ples where intense and selective breeding of a few lineages
has led to a high occurrence of undesired traits in domes-
ticated animals. Examples of such are hyperkalaemic peri-
odic paralysis (HYPP) among Quarter Horses [5] and
severe combined immunodeficiency disease (SCID) in
Arabian horses [6,7]. The negative effects of breed devel-
opment from a limited number of individuals and/or
inbreeding is also evident in dogs, with several cases of
high incidence of inherited diseases within modern pure-
breds [8].
The MCOA syndrome has a codominant mode of inherit-
ance [9] and the affected horses can be separated into two
groups depending on the type of ocular defects that they
possess; the Cyst phenotype and the MCOA phenotype.
Horses referred to as having the Cyst phenotype are pre-
sumed to be heterozygous for the mutant allele and have
a minor form of ocular abnormalities compared with
horses carrying two copies [1,9]. The presumed hetero-
zygous horses have cysts that originate from the temporal
ciliary body, peripheral retina and/or iris (Figure 1a). A
smaller number of these horses also have moderate retinal
dysplasia or retinal detachment that appears to be an
extension of these cysts [1]. The predicted homozygous
horses have multiple abnormalities, primarily affecting
the anterior segment of the eye (Figure 1b–d) [1,9]. They
encompass all clinical signs included in the Cyst pheno-
type concurrent with iris hypoplasia, iridocorneal angle
abnormalities, miosis, congenital cataracts, cornea glo-
bosa, iridocorneal adhesions and opacification, nuclear
cataract as well as pupils with a decreased or absent light
response and that do not dilate when administered mydri-
atic drugs. A single horse does not necessarily possess all
of these clinical signs and there are additional defects
detected less frequently [1,10].
MCOA has been well studied in a limited population of
the Rocky Mountain horse breed, where it was found to be
most frequent in horses with the Silver coat color (also
known as Chocolate coat color) [1]. Silver colored horses
are especially desired in this breed and thus used more fre-
quently for breeding. The consequence is an unusually
high frequency of Silver colored horses (approximately
55% of registered individuals are shown as Silver/Choco-
late), as well as horses with MCOA syndrome. The per-
centage of Silver colored horses from different breeds that
also display the Cyst phenotype or MCOA is unknown,
simply because this has not been investigated. In many of
the other horse breeds that have the Silver coat color, it is
present in a much lower frequency. As a result most Silver
colored horses are heterozygous for the Silver mutation
and hence most likely carry the milder form of this eye
Clinical signs of MCOA syndrome Figure 1
Clinical signs of MCOA syndrome. A. Oblique profile 
images of the lateral anterior segment of the right eye of a 
Rocky Mountain horse. A multiloculated cyst arising from the 
anterior ciliary body is present. B. Photograph of the right 
eye of a Rocky Mountain horse with ectropion uvea, dysco-
ria, cataract, and lens subluxation. The granula iridica is hypo-
plastic, the pupil is misshapen, and complete circumferential 
ectropion uvea is present. Nuclear cataract of the nuclear-
cortical junction is present. Vitreous is present in the ante-
rior chamber between the iris and lens secondary to poste-
rior ventral lens subluxation. C. Profile photograph of a 
Rocky Mountain Horse with Cornea Globosa. Note the 
anterior protrusion of the cornea and large corneal diame-
ter. D. Profile photograph of a Rocky Mountain Horse with a 
normal cornea. Note the normal corneal curvature and 
diameter.BMC Genetics 2008, 9:88 http://www.biomedcentral.com/1471-2156/9/88
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disorder that is more difficult to detect. The investigation
about the correlation between the Silver coat color and
MCOA is further complicated by the fact that certain horse
coat colors, for example chestnut (red), display no or little
effect of the Silver mutation. The Silver color is character-
ized by dilution of black pigment in the hair to white or
grey. The dilution is most visible in the long hairs of the
mane and tail, where the dilution results in a silver or
white mane and tail color (Figure 2). In 2006, Brunberg et
al. [11] reported that the Silver coat color is associated
with mutations in pre-melanosomal protein 17
(PMEL17). This conclusion was based on the observation
of no recombinants between PMEL17 and Silver in a ped-
igree and the identification of a haplotype, composed of
sequence variations in intron 9 and exon 11, showing
complete concordance with the presence of Silver across
six different horse breeds. In that paper, we also describe
a candidate causative missense mutation ARG618Cys that
is a non-conservative substitution at a conserved site and
mutations in the near vicinity cause a similar phenotype
in chickens [12]. The intronic mutation was found less
likely to be causative for Silver since it resides in an
intronic region not well conserved among mammalian
species. Interestingly, mutations in PMEL17 are known to
give ocular abnormalities and visual impairment in the
zebrafish mutant fading vision [13]. Microphthalmia and
colobomas have also been described in merle patterned
Dachshunds [14] and Australian Shepherds [15], a pat-
terning associated with a SINE insertion in PMEL17
according to Clark et al. [16].
In this study we firmly positioned the MCOA locus to a
4.9 Mb region on ECA6q. Further, we describe complete
linkage between three genetic markers in the interval and
the MCOA locus.
Results
Genotyping and Linkage analysis
We performed linkage analysis by genotyping 17 paternal
half-sib Rocky Mountain horse families segregating for the
MCOA locus. The number of offspring sired from each
stallion ranged from one to 29 with an average of 7.7 off-
spring per sire (Table 1). DNA was available from 41 out
of the 94 different mares within the pedigree. We geno-
typed 11 genetic markers (Table 2), spanning approxi-
mately 45 Mb on ECA6q. The rationale for selecting this
particular chromosome and region was that the PMEL17
locus is positioned on ECA6q23. Four families were used
for identification of an initial and broader interval for the
MCOA  locus (Figure 3). Genotyping was restricted to
cover a narrower region around PMEL17 for the remain-
ing 13 families. For simplicity we only present the total
number of informative meioses per marker, which is com-
piled in Table 3. According to CHROMPIC [17], one indi-
vidual was a double recombinant over a very small genetic
distance and was excluded from the analysis since it most
likely represents a genotyping error. Interestingly, one off-
spring showed non-Mendelian inheritance for the MCOA
locus. Although bred from a dam (marked red in Figure 3)
without any detectable ocular abnormalities, this individ-
ual had the MCOA phenotype. The particular mare was,
therefore, reported to be a case of nonpenetrance by Ewart
et al. 2000 [9]. Genotyping revealed that this mare was
heterozygous for all markers between UCDEQ465  and
UPP7 (see Figure 4) and thus might represent a horse with
a phenotyping error. This particular horse will be re-exam-
ined.
The results of the TWO-POINT analysis including all 17
paternal families are compiled in Table 3. We found com-
plete linkage (Θ = 0.00) between the MCOA locus and the
three markers UPP5 (z = 10.84), PMEL17ex11 (z = 12.64)
and UPP6 (z = 11.14). Marker UM015 is approximately
27 Mb upstream of UCDEQ465, which explains the lack
of linkage between this marker and the MCOA locus (see
Figure 4). We used the BUILD option with a fixed order of
markers according to the order of markers in Ensembl
A Silver colored Rocky Mountain Horse Figure 2
A Silver colored Rocky Mountain Horse. The typical 
shiny white mane and tail as well as a slightly diluted body 
color with dapples is seen in this genetically black Silver 
colored horse. The phenotype is caused by dilution of eume-
lanin in the hair to white or grey. The dilution is most visible 
in the long hairs of the mane and tail. The horse has also 
been diagnosed with MCOA.BMC Genetics 2008, 9:88 http://www.biomedcentral.com/1471-2156/9/88
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Table 1: Description of the pedigrees and extent of genotyping in each family
Number of offspring1 Number of different dams2 Number of offspring with dam genotype3 Number of markers
Stallion 1 29 (15,8,6) 22 (5,12,5,0) 29 (7,16,6) 11
Stallion 2 2 (1,0,1) 2 (0,1,1,0) 2 (0,1,1) 11
Stallion 3 10 (1,6,3) 9 (2,2,2,3) 7 (3,2,2) 11
Stallion 4 12 (2,8,2) 9 (1,2,2,4) 8 (2,3,3) 11
Stallion 5 9 (1,5,3) 7 (0,1,0,6) 1 (0,1,0) 3–5
Stallion 6 12 (5,7,0) 10 (1,0,1,8) 2 (1,0,1) 3–5
Stallion 7 7 (2,4,1) 5 (0,0,0,5) 0 (0,0,0) 3–5
Stallion 8 19 (3,14,2) 15 (0,3,1,11) 4 (0,3,1) 3–5
Stallion 9 4 (3,1,0) 3 (1,2,0,0) 4 (1,3,0) 3–5
Stallion 10 4 (1,3,0) 4 (0,0,0,4) 0 (0,0,0) 3–5
Stallion 11 7 (2,4,1) 7 (0,3,0,4) 3 (0,3,0) 3–5
Stallion 12 5 (1,2,2) 5 (0,1,0,4) 1 (0,1,0) 3–5
Stallion 13 5 (0,4,1) 3 (0,0,0,3) 0 (0,0,0) 3–5
Stallion 14 1 (0,1,0) 1 (0,0,1,0) 1 (0,0,1) 3–5
Stallion 15 2 (1,1,0) 2 (1,0,0,1) 1 (1,0,0) 3–5
Stallion 16 1 (0,1,0) 1 (0,0,1,0) 1 (0,0,1) 3–5
Stallion 17 2 (0,1,1) 2 (0,1,0,1) 1 (0,1,0) 3–5
Total: 131 65
1Phenotypes of the offspring are compiled within parenthesis (MCOA, Cyst, Healthy)
2Phenotypes of the dams are compiled within parenthesis (MCOA, Cyst, Healthy, Unexamined)
3Phenotypes of the dams are compiled within parenthesis (MCOA, Cyst, Healthy)
Table 2: Genetic markers used in the linkage analysis [18,27,28,11]
Marker Position (bp)
Ensembl [18]
Forward primer (5'-3')/
Reverse primer (5'-3')
Accession number/Reference
UM015 34558444 AGTCTGGCTGAGGATACTG
GGTGAGAAAGGAGATAAATG
GenBank: AF195133
Chowdhary et al. [27]
UCDEQ465 61228896 AACCAGTCCCTACATAGAAC
CTCACAACCAAGCATACA
GenBank: U67414
Chowdhary et al. [27]
TKY570 66793583 TCTCCGCAGCTCAAACTTTC
CTCAAAGGTGCCTGAGAAGC
GenBank: AB103788
Tozaki et al. [28]
TKY412 70589360 GTGTGGGACAGGAAGTTTGG
ATTCTTGGGTCCCCTCATCT
GenBank: AB103630
Tozaki et al. [28]
UPP5 71164435 GCACAGTCTAGGGGGTGTGT
TCTGGGCCTGGGTAGGTAGT
Probe ID: 9710436
This study
Pyroseq. PCR primers-PMEL17 ex11
Pyroseq. Seq primer-PMEL17 ex11
73665164
73665164
Biotin-TCCATTGCTTACCAGTTTCCTT
CTCACCAAAGGGGGAAGAG
GCCCTGCTTCATAAGTCTG
GenBank: DQ855465
Brunberg et al. [11]
UPP6 74667027 ATTGTACCTGGGACCCTTCC
TGTCTTTGCTTCCCAGTCCT
Probe ID: 9710437
This study
UPP7 75475262 CTTTGACACACCCTGGGAAG
CATCCACATCCTTCATTTGCT
Probe ID: 9710438
This study
UPP8 76228607 TGTCCCTGAATTCTCTGATCC
GACCTCCAGTCAAAATGAATCTG
Probe ID: 9710439
This study
TKY952 79472871 GATCGGTAAGTGTCGGGAC
TAAAATGACTGGGTGGAGAC
GenBank: AB104170
Tozaki et al. [28]
UPP9 79806071 AAAAAGAGGATTGGCAACG
TGTGTGGGGATGTAATTGGA
Probe ID: 9710440
This studyBMC Genetics 2008, 9:88 http://www.biomedcentral.com/1471-2156/9/88
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(EquCab 2, Sep 2007) [18] and allowed MCOA to be
inserted. Since three markers did not have any recombina-
tion to the MCOA locus, the disease locus could be incor-
porated equally likely anywhere in the interval between
TKY412 and UPP7 (log10_like = -25.24). According to the
horse genome sequence in Ensembl, these two markers
are positioned on Chr6:70589360 and Chr6:75475262,
respectively. The current MCOA interval thus spans
approximately 4.9 Mb. There is one reliable recombinant
on either side of this interval.
Sequencing of PMEL17 and genotyping of SNPs
PMEL17 is a candidate gene for MCOA because of its doc-
umented effect on ocular phenotypes in the zebrafish as
well as described eye defects in merle-patterned dogs. In
addition, the SNP marker positioned within the gene
showed complete linkage to the MCOA locus in our link-
age analysis. We therefore sequenced PMEL17 in three
healthy Rocky Mountain horses, three horses with the
MCOA phenotype and three with the Cyst phenotype. In
total, 6400 bp was sequenced, covering all exons and
UTRs, 370 bp upstream, 210 bp downstream as well as
full coverage of all introns except four. No additional pol-
ymorphism that associated completely with the disease
could be detected other than the two SNPs identified in
Brunberg et al. 2006 [11]. In these two SNPs, all three
MCOA horses were homozygous (Exon 11: T/T and
Intron 9: T/T) for the alleles associated with the Silver coat
color, the three healthy horses were homozygous (Exon
11: C/C and Intron 9: A/A) for the opposite alleles and the
horses with the Cyst phenotype were heterozygous (Exon
11: T/C and Intron 9: T/A) in both SNPs. The PMEL17ex11
SNP (as well as UPP5 and UPP6 also in complete linkage
with the MCOA locus) shows a near perfect correlation
between phenotype and genotype in our horse material.
Genotype information on PMEL17ex11 is shown in the
four pedigrees in Figure 3. The only discrepancy is the
healthy dam discussed above (Genotyping and Linkage
analysis section) with a heterozygous genotype (marked
in red color in Figure 3). However, since she has produced
two MCOA affected offspring, this dam is most likely a
case where the position and/or size of the cysts make them
extremely difficult to detect. In summary, the genotype
data on UPP5, PMEL17ex11 and UPP6 strongly support
the hypothesis that horses with the Cyst phenotype are
heterozygous for the mutant allele and that horses with
the MCOA phenotype are homozygous for the mutant
allele.
Discussion
In the current study we have localized the MCOA locus to
an interval on horse chromosome 6q by linkage mapping.
The locus is positioned within a 4.9 Mb interval between
microsatellite marker TKY412 and UPP7. This conclusion
is based on one reliable recombinant on either side of the
identified region. These two recombinant offspring were
genotyped for all markers used in this study and the
recombination events were clearly visualized by using the
CHROMPIC-option in CRIMAP [17]. The order of mark-
ers could confidently be established through the publicly
available horse genome sequence generated by The Broad
Institute at MIT and Harvard [19]. We used the Ensembl
genome browser to assess the precise position of geno-
typed markers. The UCSC genome browser utilizes the
initial draft assembly (EquCab1). The contig containing
PMEL17 is not anchored to a chromosome in that version.
This problem had been solved in the second assembly
(EquCab2), which is used by Ensembl. By blasting the
sequence adjacent to our genetic markers against the
human genome sequence (Ensembl, NCBI 36 assembly)
we could conclude that the order of these sequences are
identical in human and horse and that the horse MCOA
region corresponds to a region on human chromosome
12 (HSA12). Further, we provide molecular genetic evi-
Table 3: Two-point analysis between the MCOA locus and ECA6q markers
Marker Recombination fraction
Θ
Maximum LOD score
Zmax
Total number of informative meioses
MCOA – UM015 0.50 0.00 22
MCOA – UCDEQ465 0.21 1.79 51
MCOA – TKY570 0.10 4.84 55
MCOA – TKY412 0.02 10.47 79
MCOA – UPP5 0.00 12.34 76
MCOA – PMEL17ex11 0.00 18.96 93
MCOA – UPP6 0.00 17.46 127
MCOA – UPP7 0.02 12.53 99
MCOA – UPP8 0.03 10.36 84
MCOA – TKY952 0.04 7.22 68
MCOA – UPP9 0.15 0.83 23BMC Genetics 2008, 9:88 http://www.biomedcentral.com/1471-2156/9/88
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Pedigrees Figure 3
Pedigrees. Pedigrees of four of the half-sib families (sired by stallion 1–4) used in this study. Phenotype information along with 
genotype data on one genetic marker (PMEL17ex11) is shown for all individuals. Unaffected horses are indicated by open sym-
bols, half filled symbols indicate horses affected with cysts, solid symbols indicate horses affected with MCOA and unexamined 
horses are indicated by symbols enclosing a question mark. We selected the SNP PMEL17ex11 to represent the near perfect 
correlation between phenotype and genotype of the three markers in our interval that show complete linkage with the MCOA 
locus. The only discrepancy (marked in red) is a healthy dam with a heterozygous genotype. However, since she has produced 
two MCOA affected offspring, this dam is most likely a case where the position and/or size of the cysts make them extremely 
difficult to detect. NG: Not Genotyped (as DNA was not available).
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dence that the MCOA syndrome is in agreement with a
codominant mode of inheritance. MCOA affected horses
were homozygous for all three markers that were com-
pletely linked to the disease locus, horses with the Cyst
phenotype were heterozygous, while healthy horses had a
different set of alleles. Dosage effects are present in devel-
opmental eye disorders in other species, like for example
aniridia in man and Small eye in mice, that are both caused
by mutations in PAX6. Small eye mice that are hetero-
zygous display iris hypoplasia whereas homozygous mice
lack eyes, nasal cavities and display brain abnormalities
[20]. Ewart et al. [9] reported a limited number of non-
penetrance cases for the Cyst phenotype. One of these
healthy, predicted nonpenetrance cases was included in
our analysis. We could confirm that this individual was
indeed heterozygous for all markers between UCDEQ465
and UPP7, which explains the production of an MCOA
offspring. The occurrence of nonpenetrance might be
attributable to difficulties in detecting small cysts if situ-
ated just posterior to the iris. However, as most of the
nonpenetrance cases were clustered by Ewart et al. [9] to a
specific branch of the pedigree, the potential presence of
epistatic interactions between a modifier gene and the sus-
ceptibility locus cannot be excluded.
It is possible that the causative mutation for MCOA is
actually the same missense mutation in PMEL17  that
causes the Silver coat color. However, this hypothesis is
challenged by the fact that MCOA-like ocular abnormali-
ties are not known to be present among Silver colored Ice-
landic horses. To investigate this further, we are arranging
for a veterinary ophthalmologist to examine a number a
Silver colored Icelandic horses, including one that is
homozygous for the Silver mutation. We are not excluding
PMEL17 as the causative gene for MCOA but since our 4.9
Mb region contains numerous genes we are planning a
positional cloning approach to narrow down the region
before further investigation of any one candidate. It is pos-
sible that the Silver locus and the MCOA locus are merely
in linkage disequilibrium in the Rocky Mountain horse
breed and that the true causative mutation is positioned
in close proximity to PMEL17. Mutations in PMEL17 are
known to associate with ocular abnormalities in two other
species. The Zebrafish mutant fading vision demonstrates
hypopigmentation in the retinal pigment epithelium
(RPE) accompanied with vision impairment [13]. This
phenotype is caused by a nonsense mutation, which
expects to generate a truncated protein that lacks the ter-
minal 355 amino acid residues. The merle patterning in
dogs is associated with a SINE element insertion at the
boundary of intron 10 and exon 11 in PMEL17  [16].
Merle homozygous Dachshunds [14] and Australian
Shepherds [15] frequently have ocular defects such as
microphthalmia, cataract and colobomas. These defects
are similar to those of the human auditory-pigmentation
Positions of analyzed ECA6q markers Figure 4
Positions of analyzed ECA6q markers. Ten microsatel-
lite markers and one SNP marker (PMEL17ex11) spanning 
approximately 45.2 Mb were included in this study. Three 
markers showed complete linkage (recombination fraction = 
0.00) with the MCOA locus; UPP5 (z = 10.84), PMEL17ex11 (z 
= 12.64), UPP6 (z = 11.14). Our result can position the 
MCOA susceptibility locus with high confidence to the 4.9 
megabase interval between TKY412 and UPP7.BMC Genetics 2008, 9:88 http://www.biomedcentral.com/1471-2156/9/88
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disorder Waardenburg syndrome according to Clark et al.
[16]. Both the zebrafish and the dog mutants show pig-
mentation defects in both the coat and in the retinal pig-
ment epithelium (RPE). Neither of these two phenotypes
is identical with the defects observed in horses with the
MCOA syndrome.
MCOA in the Rocky Mountain horse clearly has some
overlapping phenotypes with human Anterior Segment
Dysgenesis, ASD, (Bengt Schepke pers. comm.). Clinical
classifications have been difficult in humans because of
the complex nature of the disease [21]. Therefore, to pre-
cisely state if any of the human disorders are homologous
to equine MCOA is not a simple task. Axenfeld-Rieger syn-
drome, Peters anomaly, Iris hypoplasia, Primary congeni-
tal glaucoma and Aniridia in humans do all fall under the
spectrum of ASD [21]. Anterior Segment Dysgenesis is
genetically heterogeneous in humans. Mutations in sev-
eral different genes can cause the same clinical condition.
Further, the same mutation in different individuals can
cause different forms of ASD [21]. Mutations in several
transcription factors are known to cause human ASD, for
example PITX2, FOXC1, PAX6, FOXE3 and LXM1B and
MAF [22]. None of these genes are positioned in the horse
MCOA interval. However, the Rocky Mountain horse
could at least serve as a useful model for human cornea
globosa with iris hypoplasia and congenital miosis.
Equine MCOA is generally not detectable for the
untrained eye, especially in its heterozygous state, which
leaves the breeders unaware of the problem. This fact,
together with the close linkage to the popular Silver coat
color has propagated the mutant allele in the Rocky
Mountain horse population. Thus, there is a real need for
identifying the causative gene and subsequently develop-
ing a genetic test to allow for informed breeding decisions.
Although linkage analysis is a powerful method for iden-
tification of chromosome regions for monogenic traits, it
is limited in its capacity to identify the underlying gene.
However, linkage analysis in combination with a subse-
quent identity-by-descent mapping strategy utilizing
more distantly related and/or unrelated Rocky Mountain
horses provides a better resolution. The mutation contain-
ing haplotype shared among unrelated horses are much
smaller than in family materials. Detection of causative
mutation(s) is facilitated even further if the study is
expanded to other breeds having the same phenotype. The
MCOA syndrome is present among other breeds and we
plan to use these in our future fine mapping studies. Iden-
tical ocular lesions have been observed in the Kentucky
Mountain Saddle Horse and the Mountain Pleasure
Horse. These two breeds are closely related to the Rocky
Mountain horse. The phenotype is also present in the
Morgan Horse, Belgian Draft horse and in American Min-
iature horses [1]. Thus, future studies will involve haplo-
type analysis of the MCOA region in other breeds known
to carry MCOA syndrome. This strategy will, of course, be
most effective if no locus heterogeneity exist for MCOA.
Conclusion
We have mapped the MCOA locus to ECA6q, with com-
plete linkage to the three genetic markers; UPP5,
PMEL17ex11 and UPP6. The locus can with high confi-
dence be positioned to a 4.9 Mb interval between micros-
atellite marker TKY412 and UPP7. Moreover, our results
show that the disease is in agreement with a true codomi-
nant mode of inheritance. Horses with the most severe
phenotype, displaying multiple ocular abnormalities, are
homozygous across the MCOA interval while the group of
animals having minor clinical signs is heterozygous.
Methods
Pedigrees
This study included exclusively animals listed in the
Rocky Mountain horse breed registrar. Seventeen paternal
half-sib families where MCOA is segregating were selected
for linkage analysis. To show the inheritance of MCOA in
our horse material, pedigrees from four of the stallions are
depicted in Figure 3. One hundred thirty-one offspring
were contained within the pedigree where more than half
(70 horses) of the offspring had the Cyst phenotype and
about one third (38 horses) had MCOA. Out of the 94 dif-
ferent dams (with an average of 1.4 offspring per dam)
included in the pedigree, DNA was available from 41. Out
of these, eight had MCOA, 21 had the cyst phenotype and
12 were healthy. All stallions except one were predicted
heterozygous for the disease i.e. had the Cyst phenotype.
The one stallion was healthy and had only two offspring.
The number of offspring and dams of each family, as well
as the number of individuals in each phenotype category
(MCOA, Cyst or healthy) per family are compiled in Table
1.
Phenotype assessment
Assessment of phenotype was performed as described pre-
viously [1,9]. Briefly, pupillary light reflex was first
assessed and further ophthalmic examination was con-
ducted subsequent to pupillary dilation with 1% tropica-
mide instilled in the conjunctival fornix. Examination
included direct, focal and diffuse slit lamp biomicroscopy,
indirect ophthalmoscopy and applanation tonometry.
The posterior segments of the eyes have been examined
along with the anterior parts. The examinations revealed
abnormalities of the posterior segments along with cysts
in all horses we predict to be homozygous, as well as a
fraction of the horses predicted to be heterozygous [9].
Data on histology for part of the horses used in this study,
including findings of retinal dysplasia with changes in
both the neurosensory retinal epithelium and the retinalBMC Genetics 2008, 9:88 http://www.biomedcentral.com/1471-2156/9/88
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pigmented epithelium are described in Ramsey et al. [1].
Blood samples were collected for DNA isolation at the
time of clinical examination. The phenotyping was
approved by the Michigan State University Institutional
Animal Use and Care Ethics Committee.
Genetic markers, genotyping and linkage analysis
We genotyped eleven genetic markers covering 45.2 Mb
(Table 2) of ECA6q. These included five previously iden-
tified microsatellite markers and five novel microsatellites
markers attained from the horse genome sequence
(EquCab1 Jan. 2007) [23] by displaying tracks from sim-
ple tandem repeats recognized by Tandem Repeats Finder
[24]. The SNP in exon 11 of PMEL17 that is associated
with the Silver coat color [11] was also utilized as a
marker. Primers for novel microsatellites were designed
using Primer3 [25]. The PCR reactions for amplifying mic-
rosatellites were carried out separately and in a total vol-
ume of 10 μl; 40 ng genomic DNA, 2.5 mM MgCl2, 1×
PCR Gold buffer, 0.75 units AmpliTaq Gold polymerase,
0.24 mM dNTP, 0.1 mM forward primer, 1.0 mM reverse
primer, 1.0 mM labeled M13 primer. The M13 primers
were labeled with FAM or TET. Amplified fragments were
multiplexed when possible and separated using a Mega-
BACE™1000 instrument according to manufactures
instructions. The result was analyzed in Genetic Profiler
version 2.4 (Amersham Biosciences). SNP genotype
assessment was done by pyrosequencing essentially as
described in Pielberg et al. [26]. CRI-MAP version 2.4 [17]
was used to analyze linkage between the markers and the
MCOA susceptibility locus. Since the disease is codomi-
nant, it is possible to score each individuals genotype on
the basis of their phenotype. A healthy horse was scored
as homozygous for healthy alleles, an MCOA horse as
homozygous for disease causing alleles and a horse with
the Cyst phenotype as heterozygous. The TWO-POINT
option was used to calculate recombination fractions (Θ)
and LOD scores. BUILD was used to give the most likely
position of the MCOA locus after positioning all markers
according to the horse genome sequence [18]. The output
of CHROMPIC identified unlikely double recombinants
that could reveal genotyping errors.
Sequencing of PMEL17
Primer sequences used to amplify PMEL17 can be found
in Brunberg et al. [11]. Some additional novel primers
were designed using Primer 3 [25], see additional file 1:
Table 4. The reactions were carried out as described in [11]
and results were analyzed in CodonCode Aligner version
1.6.3 (CodonCode Corporation, Dedham, MA). All
eleven exons and both UTR of PMEL17 were sequenced.
Further, all introns were fully sequenced except 1, 3, 6 and
10. Seventy base pairs (bp) were sequenced into each side
of intron 1. Thirty bp were sequenced at the beginning of
intron 3 and 80 bp at the end. Intron 6 was sequenced 390
and 590 bp at the start and end, respectively and intron 10
was sequenced 370 bp and 200 bp, respectively. We also
sequenced approximately 370 bp upstream and 210 bp
downstream of the gene.
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